The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel in Patients With Coronary Atherosclerotic Heart Disease and Planned Percutaneous Coronary Intervention: a Multi-center, Randomized, Double-blind, Triple-dummy , Parallel-controlled, Dose-exploration Phase II Trial
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Vicagrel (Primary) ; Clopidogrel
- Indications Coronary arteriosclerosis; Thrombosis
- Focus Therapeutic Use
- Sponsors Jiangsu Vcare Pharmatech
- 19 Sep 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Status changed from not yet recruiting to recruiting.
- 13 Jul 2018 New trial record